A cross-sectional study in Frontiers in Endocrinology assessed the triglyceride–glucose (TyG) index as a potential screening marker for prediabetes in children and adolescents with obesity. Hear from ReachMD's Ryan Quigley as he discusses the findings from this research and explores how the TyG index could provide an accessible tool for early risk stratification.

Head and neck involvement in atopic dermatitis significantly affects patients’ daily lives, often driving greater stigma, discomfort, and disease severity. Given this region’s impact, a post hoc analysis of the ECZTRA 1 and 2 and ECZTEND trials examined tralokinumab and found that this IL-13 inhibitor not only provided sustained reductions in head and neck EASI scores, but patients also reported better Dermatology Life Quality Index scores. Tune in to hear Dr. Raj Chovatiya dive further into the findings and their potential implications for atopic dermatitis care. Dr. Chovatiya is an Associate Professor at the Rosalind Franklin University Chicago Medical School, as well as the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago.

New research presented at the 2025 American College of Rheumatology Convergence highlights a critical link between adverse childhood experiences and mental health outcomes in adolescents with childhood-onset systemic lupus erythematosus (cSLE). In this AudioAbstract, Ryan Quigley explores the findings, the implications for trauma-informed care, and the need to assess psychosocial history in managing cSLE.

In a 2025 study investigating salivary metabolites as potential biomarkers in cystic fibrosis, researchers identified distinct metabolic patterns linked with key complications as well as correlations with lung function. In this AudioAbstract, Ryan Quigley discusses how a simple saliva sample could provide clinicians with an accessible, non-invasive tool to stratify patients, monitor therapies, and advance personalized care in cystic fibrosis. This topic was also discussed at the 2025 CHEST Annual Meeting.

A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.

In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.

Diagnosing long COVID continues to pose challenges for clinicians and patients alike. While 2024 diagnostic criteria from the National Academies aimed to make navigating it easier, the framework may raise some concerns, particularly for rheumatologists. Hear Ryan Quigley break down a commentary on the criteria published in July 2025 in Arthritis & Rheumatology that outlines why it may cause problems in the rheumatology community.

New insights from DESTINY-Breast04 highlight how trastuzumab deruxtecan (T-DXd) not only extends survival but also delays symptom deterioration in HER2-low metastatic breast cancer. In this AudioAbstract, Dr. Mimi Maeusli discusses key takeaways from the outcomes analysis and what they mean for treatment planning and patient-centered care.

A secondary analysis of eight clinical trials assessed the efficacy of ubrogepant and atogepant in both acute and preventive migraine treatments. Dive into these findings and explore implications for the future of migraine care.